Literature DB >> 26985283

Epigenetic Medicinal Chemistry.

Robert A Copeland1.   

Abstract

The past decade has seen tremendous growth in our understanding of epigenetics and chromatin remodeling. Small, organic molecule modulators of a number of chromatin modifying proteins (CMPs) have been reported over this time frame and several of these have advanced to human clinical trials. In this Viewpoint, I summarize the current state of medicinal chemistry efforts focused on epigenetic targets and attempt to provide some insight into future directions on which the community may wish to focus.

Entities:  

Year:  2015        PMID: 26985283      PMCID: PMC4753546          DOI: 10.1021/acsmedchemlett.5b00462

Source DB:  PubMed          Journal:  ACS Med Chem Lett        ISSN: 1948-5875            Impact factor:   4.345


  13 in total

Review 1.  Epigenetic protein families: a new frontier for drug discovery.

Authors:  Cheryl H Arrowsmith; Chas Bountra; Paul V Fish; Kevin Lee; Matthieu Schapira
Journal:  Nat Rev Drug Discov       Date:  2012-04-13       Impact factor: 84.694

2.  Genetics of natural populations; recombination and variability in populations of Drosophila pseudoobscura.

Authors:  T DOBZHANSKY
Journal:  Genetics       Date:  1946-05       Impact factor: 4.562

3.  EHMT1 and EHMT2 inhibition induces fetal hemoglobin expression.

Authors:  Aline Renneville; Peter Van Galen; Matthew C Canver; Marie McConkey; John M Krill-Burger; David M Dorfman; Edward B Holson; Bradley E Bernstein; Stuart H Orkin; Daniel E Bauer; Benjamin L Ebert
Journal:  Blood       Date:  2015-08-28       Impact factor: 22.113

4.  Inhibition of G9a methyltransferase stimulates fetal hemoglobin production by facilitating LCR/γ-globin looping.

Authors:  Ivan Krivega; Colleen Byrnes; Jaira F de Vasconcellos; Y Terry Lee; Megha Kaushal; Ann Dean; Jeffery L Miller
Journal:  Blood       Date:  2015-05-15       Impact factor: 22.113

Review 5.  Small molecule control of chromatin remodeling.

Authors:  Aidan Finley; Robert A Copeland
Journal:  Chem Biol       Date:  2014-09-18

6.  Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms.

Authors:  Steven D Gore; Stephen Baylin; Elizabeth Sugar; Hetty Carraway; Carole B Miller; Michael Carducci; Michael Grever; Oliver Galm; Tianna Dauses; Judith E Karp; Michelle A Rudek; Ming Zhao; B Douglas Smith; Jasper Manning; Anchalee Jiemjit; George Dover; Abbie Mays; James Zwiebel; Anthony Murgo; Li-Jun Weng; James G Herman
Journal:  Cancer Res       Date:  2006-06-15       Impact factor: 12.701

7.  Durable tumor regression in genetically altered malignant rhabdoid tumors by inhibition of methyltransferase EZH2.

Authors:  Sarah K Knutson; Natalie M Warholic; Tim J Wigle; Christine R Klaus; Christina J Allain; Alejandra Raimondi; Margaret Porter Scott; Richard Chesworth; Mikel P Moyer; Robert A Copeland; Victoria M Richon; Roy M Pollock; Kevin W Kuntz; Heike Keilhack
Journal:  Proc Natl Acad Sci U S A       Date:  2013-04-25       Impact factor: 11.205

8.  DOT1L inhibitor EPZ-5676 displays synergistic antiproliferative activity in combination with standard of care drugs and hypomethylating agents in MLL-rearranged leukemia cells.

Authors:  Christine R Klaus; Dorothy Iwanowicz; Danielle Johnston; Carly A Campbell; Jesse J Smith; Mikel P Moyer; Robert A Copeland; Edward J Olhava; Margaret Porter Scott; Roy M Pollock; Scott R Daigle; Alejandra Raimondi
Journal:  J Pharmacol Exp Ther       Date:  2014-07-03       Impact factor: 4.030

Review 9.  Epigenetics in human disease and prospects for epigenetic therapy.

Authors:  Gerda Egger; Gangning Liang; Ana Aparicio; Peter A Jones
Journal:  Nature       Date:  2004-05-27       Impact factor: 49.962

10.  Loss of BAP1 function leads to EZH2-dependent transformation.

Authors:  Lindsay M LaFave; Wendy Béguelin; Richard Koche; Matt Teater; Barbara Spitzer; Alan Chramiec; Efthymia Papalexi; Matthew D Keller; Todd Hricik; Katerina Konstantinoff; Jean-Baptiste Micol; Benjamin Durham; Sarah K Knutson; John E Campbell; Gil Blum; Xinxu Shi; Emma H Doud; Andrei V Krivtsov; Young Rock Chung; Inna Khodos; Elisa de Stanchina; Ouathek Ouerfelli; Prasad S Adusumilli; Paul M Thomas; Neil L Kelleher; Minkui Luo; Heike Keilhack; Omar Abdel-Wahab; Ari Melnick; Scott A Armstrong; Ross L Levine
Journal:  Nat Med       Date:  2015-10-05       Impact factor: 53.440

View more
  1 in total

1.  Rapid and Reliable Binding Affinity Prediction of Bromodomain Inhibitors: A Computational Study.

Authors:  Shunzhou Wan; Agastya P Bhati; Stefan J Zasada; Ian Wall; Darren Green; Paul Bamborough; Peter V Coveney
Journal:  J Chem Theory Comput       Date:  2017-01-18       Impact factor: 6.006

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.